AVIR

AVIR is not a fundamentals story — it is a clinical-stage biopharma with no commercial product. The eye-catching P/S of 1.1 is an artifact: the only real revenue was FY2021's $351M (a one-time COVID collaboration), and every year since has been pure burn (-$116M, -$136M, -$168M, -$158M). The 10-K is explicit: 'We have no products that have generated any commercial revenue' and 'We expect to incur operating losses in 2026 and for the foreseeable future,' against a $522.6M accumulated deficit. Operating margin (-51.5%), net margin (-45.1%) and ROE (-57.5%) are meaningless here except to confirm the company lives or dies on trial data, not the income statement.

What keeps this out of 'avoid' is the balance sheet and the setup. Liabilities/equity is just 0.14x — there is essentially no debt. With ~$311M of current assets against ~$40M of current liabilities and a ~$132M annual operating burn, the company has roughly two-plus years of runway, enough to fund it through both catalysts and the targeted March 2027 NDA. At $4.98 the $397M market cap sits close to the ~$275M of stockholders' equity, so the pipeline premium is modest — the cash cushion limits how far the stock falls on a wipeout, though a failed Phase 3 would still take it toward book/cash value.